{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:23:56Z","timestamp":1790965436388,"version":"4.1.0"},"reference-count":80,"publisher":"The Journal of Food and Drug Analysis (JFDA), Food and Drug Administration, Taiwan (TFDA)","issue":"4","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,13]],"date-time":"2015-07-13T00:00:00Z","timestamp":1436745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jfda-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Food and Drug Analysis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.jfda.2015.04.008","type":"journal-article","created":{"date-parts":[[2015,5,21]],"date-time":"2015-05-21T20:36:31Z","timestamp":1432240591000},"page":"595-608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Recent trends in specialty pharma business model"],"prefix":"10.38212","volume":"23","author":[{"given":"Mannching Sherry","family":"Ku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"25385","reference":[{"key":"10.1016\/j.jfda.2015.04.008_bib1","first-page":"371","article-title":"How to define specialty Pharmaceuticals\u2013A systematic review","volume":"2","author":"Blaser","year":"2010","journal-title":"Am J Pharm Benefits"},{"key":"10.1016\/j.jfda.2015.04.008_bib2","series-title":"Specialty Pharmaceuticals: Shining light on spec R&D","author":"Risinger","year":"2011"},{"key":"10.1016\/j.jfda.2015.04.008_bib3","series-title":"Annual Report","author":"Teva","year":"2012"},{"key":"10.1016\/j.jfda.2015.04.008_bib4","unstructured":"Drugs@FDA Prescribing Information for COPAXONE, NDA no. 020622."},{"key":"10.1016\/j.jfda.2015.04.008_bib5","unstructured":"Drugs@FDA Supplemental Approval Letter on NDA 020622\/S-089 Copaxone 40 mg per mL."},{"key":"10.1016\/j.jfda.2015.04.008_bib6","unstructured":"Teva Press Release. Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) provides its current outlook for non-GAAP financial performance for the year ending December 31, 2015. Dec. 11, 2014."},{"key":"10.1016\/j.jfda.2015.04.008_bib7","unstructured":"Catamaran (formerly informedRx) Prescription Management Services. Available at http:\/\/www.catamaranrx.com\/Insights\/Trend-Report\/accessed 2014\/12\/20."},{"key":"10.1016\/j.jfda.2015.04.008_bib8","unstructured":"Drugs@FDA Prescribing Information for EpiPen\u00ae Auto-Injector, NDA no. 019430."},{"key":"10.1016\/j.jfda.2015.04.008_bib9","unstructured":"Smithon Stocks. Available at http:\/\/smithonstocks.com\/antares-settlement-of-litigation-on-epipen-is-a-positive-ais-3-08\/accessed 2014\/12\/20."},{"key":"10.1016\/j.jfda.2015.04.008_bib10","unstructured":"Drugs@FDA Prescribing Information for EMSAM, NDA no. 021336."},{"key":"10.1016\/j.jfda.2015.04.008_bib11","unstructured":"Bloomberg News \u201cWatson to Buy TheraTech for Its Drug Technology\u201d October 26, 1998."},{"key":"10.1016\/j.jfda.2015.04.008_bib12","series-title":"Actavis is buying Botox-maker Allergan for $66bn (\u00a342bn) to create one of the top ten biggest pharmaceutical companies in the world","author":"BBC News","year":"2014"},{"key":"10.1016\/j.jfda.2015.04.008_bib13","unstructured":"Bloomberg News. Available at http:\/\/www.bloomberg.com\/news\/2014-11-17\/actavis-surges-to-top-drugmaker-ranks-with-plan-to-broaden-sales.html. Accessed 2014\/12\/20."},{"key":"10.1016\/j.jfda.2015.04.008_bib14","unstructured":"Mylan News Release. Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business. 2010\/7\/14."},{"key":"10.1016\/j.jfda.2015.04.008_bib15","unstructured":"Mylan News Release. Mylan to Acquire Pfizer Respiratory Delivery Platform."},{"key":"10.1016\/j.jfda.2015.04.008_bib16","unstructured":"Sandoz Press Release. 2005 9 13 Sandoz Files Lawsuit Seeking FDA Ruling on Omnitrope. 2011\/11\/9."},{"key":"10.1016\/j.jfda.2015.04.008_bib17","series-title":"Specialty Market Report","author":"Health","year":"2010"},{"key":"10.1016\/j.jfda.2015.04.008_bib18","article-title":"Despite Billions for Discoveries, Pipeline of Drugs is Far from Full","author":"Pollack","year":"2002","journal-title":"The New York Times"},{"key":"10.1016\/j.jfda.2015.04.008_bib19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0167-6296(02)00126-1","article-title":"The price of innovation: new estimates of drug development costs","volume":"22","author":"DiMasi","year":"2003","journal-title":"J Health Econ"},{"key":"10.1016\/j.jfda.2015.04.008_bib20","article-title":"Rebuilding Big Pharma's Business Model","author":"Singh","year":"2003","journal-title":"In\u00a0Vivo"},{"key":"10.1016\/j.jfda.2015.04.008_bib21","series-title":"Changing Patterns of Pharmaceutical Innovation: A Research Report","first-page":"p.15","author":"The National Institute for Health Care Management Research and Educational Foundation","year":"2002"},{"key":"10.1016\/j.jfda.2015.04.008_bib22","first-page":"1","article-title":"Efforts to reduce the impact of generic competition for lipitor","volume":"83","author":"Purvisa","year":"2013","journal-title":"AARP Public Policy Institute Insight"},{"key":"10.1016\/j.jfda.2015.04.008_bib23","doi-asserted-by":"crossref","first-page":"e1001460","DOI":"10.1371\/journal.pmed.1001460","article-title":"Patented drug extension strategies on healthcare spending: a cost-evaluation analysis","volume":"10","author":"Vernaz","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.jfda.2015.04.008_bib24","series-title":"FDA clears 'generic Prozac' for sale","author":"CNN News Washington","year":"2001"},{"key":"10.1016\/j.jfda.2015.04.008_bib25","series-title":"Beyond Lifecycle Management Optimizing Performance Following Patent Expiry 2004","author":"Tuttle","year":"2004"},{"key":"10.1016\/j.jfda.2015.04.008_bib26","series-title":"Annual Report","author":"Pfizer","year":"2012"},{"key":"10.1016\/j.jfda.2015.04.008_bib27","series-title":"The War Over Lipitor\u2014Full Version","author":"Eban","year":"2011"},{"key":"10.1016\/j.jfda.2015.04.008_bib28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1056\/NEJMp1113112","article-title":"Generic atorvastatin and health care costs","volume":"366","author":"Jackevicius","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfda.2015.04.008_bib29","article-title":"Pharmacies Sue Pfizer Over Lipitor","author":"Loftus","year":"2012","journal-title":"Wall Street Journal"},{"key":"10.1016\/j.jfda.2015.04.008_bib30","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1740-1461.2011.01235.x","article-title":"When do generics challenge drug patents?","volume":"84","author":"Hemphill","year":"2011","journal-title":"J Empir Leg Stud"},{"key":"10.1016\/j.jfda.2015.04.008_bib31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hec.1454","article-title":"Spending on new drug development","volume":"19","author":"Adams","year":"2010","journal-title":"Health Econ"},{"key":"10.1016\/j.jfda.2015.04.008_bib32","first-page":"7","article-title":"Trends in Pharmaceutical Dealmaking","volume":"12","author":"Terry","year":"2010","journal-title":"Business Development & Licensing Journal"},{"key":"10.1016\/j.jfda.2015.04.008_bib33","first-page":"9","article-title":"Masters of reinvention","author":"Macleod","year":"2007","journal-title":"Drug Delivery"},{"key":"10.1016\/j.jfda.2015.04.008_bib34","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/clpt.2009.286","article-title":"Proof of concept: A PhRMA position paper with recommendations for best practice","volume":"87","author":"Cartwright","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jfda.2015.04.008_bib35","unstructured":"Biologics Price Competition and Innovation Act of 2009 (BPCIA). Available at www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/UCM216146 Accessed 2014\/12\/5."},{"key":"10.1016\/j.jfda.2015.04.008_bib36","article-title":"Celltrion Submits Remicade Biosimilar to the FDA","author":"Grogan","year":"2014","journal-title":"World News"},{"key":"10.1016\/j.jfda.2015.04.008_bib37","series-title":"Positive Phase 3 Study Results Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Plaque Psoriasis","author":"Amgen News Release","year":"2014"},{"key":"10.1016\/j.jfda.2015.04.008_bib38","article-title":"New Drug Development: Estimating Entry from Human Clinical Trials","volume":"262","author":"Adams","year":"2003","journal-title":"FTC Working Paper#"},{"key":"10.1016\/j.jfda.2015.04.008_bib39","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nchembio.581","article-title":"Getting pharmaceutical R&D back on target","volume":"7","author":"Bunnage","year":"2011","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.jfda.2015.04.008_bib40","unstructured":"Data from the Pharmaceutical Benchmarking Forum. Available at http:\/\/kmrgroup.com\/ForumsPharma.html. Accessed 2011\/05\/17."},{"key":"10.1016\/j.jfda.2015.04.008_bib41","first-page":"1","article-title":"Phase II failures: 2008\u20132010","volume":"10","author":"Thomson Reuters Life Science Consulting Staff","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jfda.2015.04.008_bib42","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.drudis.2011.12.020","article-title":"Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival","volume":"17","author":"Morgan","year":"2012","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jfda.2015.04.008_bib43","series-title":"Open innovation: The new imperative for creating and profiting from technology","author":"Chesbrough","year":"2003"},{"key":"10.1016\/j.jfda.2015.04.008_bib44","series-title":"Open business models: how to thrive in the new innovation landscape","author":"Chesbrough","year":"2006"},{"key":"10.1016\/j.jfda.2015.04.008_bib45","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrd2912","article-title":"Sales from licensed and acquired products to increase by 2013","volume":"8","author":"Opinion","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jfda.2015.04.008_bib46","series-title":"Price Waterhouse Coopers 2009 Special Report: Pharma 2020: marketing the future","year":"2009"},{"key":"10.1016\/j.jfda.2015.04.008_bib47","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/mde.1360","article-title":"The cost of biopharmaceutical R&D: is biotech different?","volume":"28","author":"DiMasi","year":"2007","journal-title":"MDE Manag Decis Econ"},{"key":"10.1016\/j.jfda.2015.04.008_bib48","unstructured":"National Cancer Institute: Success Story Taxol. Available at http:\/\/dtp.nci.nih.gov\/timeline\/flash\/success_stories\/S2_taxol.htm Accessed 2014\/12\/31."},{"key":"10.1016\/j.jfda.2015.04.008_bib49","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/373370a0","article-title":"Names for hi-jacking","volume":"373","author":"Editorial Opinion","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.jfda.2015.04.008_bib50","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nm0509-502","article-title":"Open innovation networks between academia and industry: an imperative for breakthrough therapies","volume":"15","author":"Melese","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.jfda.2015.04.008_bib51","series-title":"Science Business: The Promise, the Reality, and the Future of Biotech","first-page":"1","author":"Pisano","year":"2006"},{"key":"10.1016\/j.jfda.2015.04.008_bib52","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nrd4164","article-title":"Does size matter in R&D productivity If not, what does?","volume":"12","author":"Ringel","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jfda.2015.04.008_bib53","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/08956308.2000.11671362","article-title":"Drug industry mergers won't necessarily benefit R&D","volume":"43","author":"Henderson","year":"2000","journal-title":"Res Technol Manage"},{"key":"10.1016\/j.jfda.2015.04.008_bib54","article-title":"New Frontiers in Pharma R&D Investment","author":"David","year":"2010","journal-title":"Mickinsey Quarterly"},{"key":"10.1016\/j.jfda.2015.04.008_bib55","unstructured":"Lilly and Pfizer Company 2010 Annual Reports. Indianapolis, IN; NY, NY."},{"key":"10.1016\/j.jfda.2015.04.008_bib56","article-title":"Shire Terminate Year's Biggest Deal","author":"Beckerma","year":"2014","journal-title":"Wall Street J"},{"key":"10.1016\/j.jfda.2015.04.008_bib57","series-title":"Specialty Pharmas reduce the risk","author":"Van Brunt","year":"2004"},{"key":"10.1016\/j.jfda.2015.04.008_bib58","series-title":"Standing Out from the Crowd","author":"Brandweiner","year":"2010"},{"key":"10.1016\/j.jfda.2015.04.008_bib59","series-title":"Rare Disease Act of 2002","first-page":"107","author":"US 107th Congress","year":"2002"},{"key":"10.1016\/j.jfda.2015.04.008_bib60","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.drudis.2013.11.009","article-title":"Financing drug discovery for orphan diseases","volume":"19","author":"Fagnan","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jfda.2015.04.008_bib61","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"Timeline: The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jfda.2015.04.008_bib62","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.jfda.2015.04.008_bib63","unstructured":"NICE technology appraisal guidance 171. Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy. Issued: June 2009 last modified: April 2014."},{"key":"10.1016\/j.jfda.2015.04.008_bib64","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1517\/14656566.9.11.1987","article-title":"Imiglucerase and its use for the treatment of Gaucher's disease","volume":"9","author":"Weinreb","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jfda.2015.04.008_bib65","series-title":"Annual Report","author":"Genzyme","year":"2010"},{"key":"10.1016\/j.jfda.2015.04.008_bib66","series-title":"2011 Results Benefit from Genzyme Acquisition","author":"Sanofi Press Release","year":"2012"},{"key":"10.1016\/j.jfda.2015.04.008_bib67","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1056\/NEJMp1003126","article-title":"Incentives for drug development - the curious case of colchicine","volume":"362","author":"Kesselheim","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfda.2015.04.008_bib68","unstructured":"US Congress. 505(b)(2) under 21 CFR 314.54. Patent certifications under 21 CFR 314.50(i). Notice of certain patent certifications to the NDA holder and patent owner under 21 CFR 314.52."},{"key":"10.1016\/j.jfda.2015.04.008_bib69","first-page":"1484","article-title":"Article to the Editor","volume":"363","author":"Woodcock","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfda.2015.04.008_bib70","first-page":"1484","article-title":"Author\/Editor Response","volume":"363","author":"Kesselheim","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfda.2015.04.008_bib71","series-title":"Takeda to Acquire URL Pharma","author":"Takeda News Release","year":"2012"},{"key":"10.1016\/j.jfda.2015.04.008_bib72","series-title":"Qsymia and Belviq drugs for obesity, Weight Loss","author":"Grohol","year":"2012"},{"key":"10.1016\/j.jfda.2015.04.008_bib73","series-title":"FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for Qnexa","author":"Vivus Press Release","year":"2010"},{"key":"10.1016\/j.jfda.2015.04.008_bib74","unstructured":"Topamax Medication Guide. Available at http:\/\/www.fda.govdownloadsDrugsDrugSafetyUCM152837.pdf Accessed 12\/31\/2014."},{"key":"10.1016\/j.jfda.2015.04.008_bib75","series-title":"Actavis slaps struggling Vivus with generic threat","author":"Helfand","year":"2014"},{"key":"10.1016\/j.jfda.2015.04.008_bib76","series-title":"Vivus hits Actavis with Qsymia patent-infringement lawsuit","author":"Helfand","year":"2014"},{"key":"10.1016\/j.jfda.2015.04.008_bib77","series-title":"Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting","author":"Vivus Press Release","year":"2009"},{"key":"10.1016\/j.jfda.2015.04.008_bib78","unstructured":"US Congress. NDA supplement under Food, Drug, and Cosmetic Act, Section 505; 21 USC 355."},{"key":"10.1016\/j.jfda.2015.04.008_bib79","unstructured":"US Congress. The Drug Price Competition and Patent Term Restoration Act (Public Law 98-417), informally known as the Hatch-Waxman Act."},{"key":"10.1016\/j.jfda.2015.04.008_bib80","series-title":"Abbreviated New Drug Application Regulations; Patent and Exclusivity Provisions; Final Rule","author":"Federal Register","year":"1994"}],"container-title":["Journal of Food and Drug Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1021949815000575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1021949815000575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1021949815000575?httpAccept=text\/plain","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T18:17:06Z","timestamp":1666635426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1021949815000575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1021949815000575"],"URL":"https:\/\/doi.org\/10.1016\/j.jfda.2015.04.008","relation":{},"ISSN":["1021-9498"],"issn-type":[{"value":"1021-9498","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent trends in specialty pharma business model","name":"articletitle","label":"Article Title"},{"value":"Journal of Food and Drug Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfda.2015.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}